{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for "Cellular or Molecular Interactions [MoA]|Receptor Interactions [MoA]" in comments (approximate match)
Status:
US Approved Rx
(2001)
Source:
NDA021288
(2001)
Source URL:
First approved in 2000
Source:
NDA020715
Source URL:
Class:
PROTEIN
Conditions:
Triptorelin is a synthetic decapeptide agonist analog of luteinizing hormone releasing hormone (LHRH). It works by decreasing the production of certain hormones, which reduces testosterone levels in the body. Animal studies comparing triptorelin to native GnRH found that triptorelin had 13 fold higher releasing activity for luteinizing hormone, and 21-fold higher releasing activity for follicle-stimulating hormone. Triptorelin is indicated for the palliative treatment of advanced prostate cancer.
Status:
US Approved Rx
(2019)
Source:
BLA761073
(2019)
Source URL:
First approved in 1998
Source:
BLA103792
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2019)
Source:
BLA761086
(2019)
Source URL:
First approved in 1998
Source:
BLA103772
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103795
(1998)
Source URL:
First approved in 1998
Source:
BLA103795
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1998)
Source:
BLA103764
(1998)
Source URL:
First approved in 1998
Source:
BLA103764
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
BLA021765
(2004)
Source URL:
First approved in 1997
Source:
BLA020378
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2016)
Source:
BLA761029
(2016)
Source URL:
First approved in 1997
Source:
Zenapax
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2009)
Source:
BLA125274
(2009)
Source URL:
First approved in 1989
Source:
BLA103000
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2000)
Source:
BLA021149
(2000)
Source URL:
First approved in 1976
Source:
BLA017692
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(1973)
Source:
BLA017067
(1973)
Source URL:
First approved in 1940
Class:
PROTEIN
